Turnstone BiologicsTSBX
TSBX
About: Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
Employees: 8
0
Funds holding %
of 7,326 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
3.04% less ownership
Funds ownership: 47.97% [Q4 2024] → 44.93% (-3.04%) [Q1 2025]
18% less funds holding
Funds holding: 28 [Q4 2024] → 23 (-5) [Q1 2025]
23% less capital invested
Capital invested by funds: $5.51M [Q4 2024] → $4.26M (-$1.25M) [Q1 2025]
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
Research analyst outlook
We haven’t received any recent analyst ratings for TSBX.
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Turnstone Biologics Corp. (NASDAQ: TSBX)
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Turnstone Biologics Corp. (NASDAQ: TSBX ) related to its sale to XOMA Royalty Corporation in which existing Turnstone shareholders will receive $0.34 in cash per share and one non-transferable contingent value right. Is it a fair deal?
Neutral
Business Wire
1 month ago
TSBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Turnstone Biologics Corp. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Turnstone Biologics Corp. (NASDAQ: TSBX) to XOMA Royalty Corporation for $0.34 in cash per share plus one non-transferable contingent value right is fair to Turnstone shareholders. Halper Sadeh encourages Turnstone shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper.
Neutral
GlobeNewsWire
2 months ago
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights
SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (“Selected TIL”) therapy, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates. Corporate Updates In January 2025, Turnstone made the determination to discontinue all TIDAL-01 clinical studies and halted further development of the program.
Neutral
GlobeNewsWire
4 months ago
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (“Selected TIL”) therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In November 2024, the Company presented preclinical data on its Selected TIL therapies at the 2024 Society for Immunotherapy of Cancer (“SITC”) Annual Meeting.
Positive
Zacks Investment Research
5 months ago
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?
Turnstone Biologics Corp. (TSBX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
8 months ago
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Turnstone's next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced it will be presenting two posters highlighting preclinical data on methods for TIL selection at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024 in Houston, Texas. “We remain confident that delivering a TIL-based product with a higher proportion of tumor-reactive T cells is the key to extending the clinical application of TILs across a broader range of solid tumors,” said David Stojdl, Ph.D.
Neutral
Benzinga
11 months ago
Turnstone Biologics Shifts Focus To 'High Unmet Medical Need' Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy Study
Turnstone Biologics Corp. TSBX stock is trading lower after the company released initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite-stable colorectal cancer (MSS mCRC) on Thursday.
Negative
InvestorPlace
11 months ago
Why Is Turnstone Biologics (TSBX) Stock Down 38% Today?
Turnstone Biologics (NASDAQ: TSBX ) stock is falling on Thursday following the release of the clinical-stage biotechnology company's earnings report. The bad news pulling TSBX stock down today is the company's diluted earnings per share of -92 cents.
Neutral
GlobeNewsWire
11 months ago
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations into 3Q 2025 SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the second quarter ended June 30, 2024, and provided recent business highlights. “We have continued to bolster our position by making advances across our pipeline and corporate operations in the second quarter of 2024.
Neutral
GlobeNewsWire
11 months ago
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
Overall response rate (“ORR”) of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC Complete response achieved in heavily pre-treated late line patient with progression free survival extending beyond one year Favorable tolerability profile and demonstrated manufacturing success Product characterization and translational data support biological hypothesis for Selected TILs SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported positive initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite stable colorectal cancer (“MSS mCRC”). Turnstone's Phase 1 STARLING trial is an ongoing muti-site, first-in-human, non-randomized, open label, single-dose study, and is evaluating the safety, tolerability, and clinical activity of TIDAL-01.
Charts implemented using Lightweight Charts™